Global Residual DNA Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
Global Residual DNA Testing Market: by Type (qPCR-based Residual DNA Testing, PCR-based Residual DNA Testing, DNA Hybridization, ELISA-based Residual DNA Testing, Others), Application (Biopharmaceuticals, Vaccines, Gene Therapy, Cell Therapy, Blood and Plasma Products, Others), Distribution Channels (Direct Sales, Distributors, Online Sales, Others), Technology (qPCR, PCR, Hybridization, ELISA, Capillary Electrophoresis, Others), Organization Size (Small, Medium, Large) and By Global â Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 17-04-2026 | Format: PDF | Report ID:21948 | Author: Ankita R
Global Residual DNA Testing Market Size, Share & Trends Analysis, 2020-2035
The global residual DNA testing market is witnessing robust demand, driven by increasingly stringent regulatory standards for biopharmaceutical manufacturing and the rapid expansion of gene and cell therapy pipelines. Cutting-edge technologies such as qPCR, PCR, and DNA hybridization are enhancing sensitivity and reliability, shaping new norms in quality assurance for biologics. The market is accelerating in North America, Europe, and Asia-Pacific, with biopharmaceuticals, vaccines, and emerging therapies among the foremost applications for residual DNA quantification. Key players are focused on technical advancements, partnership agreements, and service expansion to meet the rising needs of vaccine manufacturers, gene therapy firms, and blood product providers while ensuring alignment with global regulatory compliance.
Latest Market Dynamics
Key Drivers
Rising biopharmaceutical production and increasing regulatory stringency for product safety, as reflected in FDA and EMA guidelines. For example, in 2025, Thermo Fisher Scientific
expanded its qPCR automation platforms to support higher-throughput quality control for vaccine manufacturing.
Growth in gene and cell therapy developments necessitating stricter residual DNA quantification. Merck KGaA launched updated residual DNA detection services in early 2025 to support advanced cell therapy projects, addressing next-generation therapeutic safety requirements.
Key Trends
Automation and digitization of residual DNA testing laboratories, as seen with Bio-Rad Laboratories introducing digital PCR innovations for standardized workflows in February 2025.
Expansion of contract testing and CRO partnerships. Eurofins Scientific signed new agreements in January 2025 to provide comprehensive DNA residue testing services to leading vaccine and plasma product makers.
Key Opportunities
Emerging markets in Asia-Pacific presenting accelerating opportunities, driven by local biopharma investment. GenScript Biotech formed a strategic partnership in March 2025 with a leading Indian biosimilars developer to address rising demand for cGMP-compliant DNA analysis.
Development of miniaturized and faster qPCR assays for point-of-use testing. In 2025, Agilent Technologies introduced a compact qPCR platform enabling on-site residual DNA quantification within manufacturing suites.
Key Challenges
Technical difficulties in differentiating DNA contaminants between closely related cell lines. Promega Corporation enhanced their reference standard kits in April 2025 to address cross-reactivity issues seen in legacy PCR protocols.
Maintaining cost-effectiveness while integrating higher sensitivity platforms. Charles River Laboratories increased its service menu in May 2025, but cited the challenge of balancing advanced technology adoption with affordability for smaller manufacturers.
Key Restraints
High capital investment and operational costs associated with setting up fully automated residual DNA testing laboratories. In February 2025, Lonza Group highlighted notable CapEx burdens when upgrading QC infrastructure across its new biomanufacturing sites.
Limited standardization across global regulatory agencies causing delays in product approvals. SGS S.A. reported in March 2025 that companies entering multiple regions face complex validation and compliance hurdles.
In 2025, qPCR-based residual DNA testing is the leading segment, capturing the largest share of the global market due to its superior sensitivity, specificity, and rapid turnaround. PCR-based and hybridization methods continue to see growth as cost-competitive options, especially in resource-limited settings, while ELISA and capillary electrophoresis are selected for specialized applications. Industry preferences are shaped by product throughput, technology integration possibilities, and validation requirements for regulatory compliance.
Biopharmaceutical applications represent the dominant market share for residual DNA testing in 2025, followed by vaccines and gene therapy use cases. The intensive regulatory oversight over biologics manufacturing propels demand, with rising adoption in gene and cell therapy reflecting the pipeline of advanced medicines. Blood and plasma products and other therapeutic categories maintain stable shares as these categories are subjected to global DNA residual limits. This segmentation highlights the foundational role of DNA testing across the continuum of complex biologics and personalized medicine.
Global Residual DNA Testing Market Revenue (2020-2035)
Over the forecast period, the global residual DNA testing market is projected to rise significantly, with revenue growing from 815 Million USD in 2020 to nearly 2,070 Million USD by 2035. The upward trajectory is primarily attributed to expanding applications in biopharmaceutical manufacturing, escalating compliance needs, and the proliferation of gene and cell therapies. The compound annual growth rate remains robust, reflecting technology upgrades and the entry of emerging market manufacturers aligning with international standards.
Global Residual DNA Testing Market YOY (%), 2020-2035
The year-over-year growth rate for the residual DNA testing market remains healthy, with a peak in the mid-2020s driven by rapid biopharmaceutical expansion and regulatory tightening. As the market matures, YOY rates normalize in the 6%-8% range by 2035, reflecting ongoing advancements in process efficiency, increased automation, and steady product innovation adoption worldwide.
North America remains the largest regional market for residual DNA testing in 2025, underpinned by mature biopharmaceutical infrastructure and leading regulatory frameworks. Europe holds a strong second position, benefitting from established healthcare standards and investment in advanced therapeutics. Asia-Pacific demonstrates dynamic growth with increasing adoption of biologics and regulatory harmonization, while other regions retain modest but growing market shares aligned with local biomanufacturing activities.
The global residual DNA testing market is moderately consolidated, with Thermo Fisher Scientific, Merck KGaA, and Bio-Rad Laboratories holding the top market shares in 2025 owing to their robust assay portfolios and global reach. Emerging companies are gaining traction by offering innovative platforms and tailored service models, driving specializations across product sectors and geographies. Partnerships, M&A activities, and targeted R&D investment by established players support competitive differentiation.
Biopharmaceutical manufacturers constitute the largest buyer segment in the residual DNA testing market in 2025, as stringent compliance needs drive their procurement of advanced testing solutions. Vaccine producers and contract research/testing organizations also make up sizable shares, propelled by robust outsourcing trends and rapid response to emerging health challenges. Blood and plasma product manufacturers and specialized gene/cell therapy firms represent focused but expanding buyer categories.
Study Coverage
Metrics
Details
Years
2020-2035
Base Year
2025
Market Size
1200
Regions
North America, Europe, Asia-Pacific, South America, Middle East, Africa
Segments
qPCR-based Residual DNA Testing, PCR-based Residual DNA Testing, DNA Hybridization, ELISA-based Residual DNA Testing, Capillary Electrophoresis, Others; Biopharmaceuticals, Vaccines, Gene Therapy, Cell Therapy, Blood and Plasma Products, Others
June 2024: Thermo Fisher Scientific unveiled a fully automated qPCR sample prep module for streamlined residual DNA detection in vaccines.
July 2024: Merck KGaA expanded its digital PCR testing services, announcing global partnerships with new biotech clients in Europe and Asia.
August 2024: Bio-Rad Laboratories launched an advanced reference standard kit addressing gene therapy contamination control.
September 2024: Charles River Laboratories announced the opening of a next-generation biomanufacturing QC center dedicated to high-throughput DNA testing.
October 2024: Eurofins Scientific partnered with leading plasma product manufacturers for bespoke, rapid-turnaround DNA residue analytics.
Frequently Asked Questions
About the Author
Ankita R
Lead Industry Analyst
Ankita R is a Lead Industry Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Ankita R brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Ankita R has helped organizations translate data into actionable growth strategies.
